<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311168</url>
  </required_header>
  <id_info>
    <org_study_id>CRD343</org_study_id>
    <nct_id>NCT00311168</nct_id>
  </id_info>
  <brief_title>Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)</brief_title>
  <official_title>Reduce Ventricular Pacing Using Ventricular Intrinsic Preference: VIP™ Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the VIP™ feature (available in dual&#xD;
      chamber Victory® devices) to reduce unnecessary RV pacing, and to determine if patients with&#xD;
      implanted SJM pacemakers will benefit by using VIP™ rather than only a programmed AV/PV&#xD;
      delay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Intrinsic Ventricular Events</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measured evaluated the difference in the percentage of intrinsic ventricular events between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Arrhythmias</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the difference in the percentage of time a patient spent in atrial tachycardia/atrial fibrillation (arrhythmia burden) calculated by the device between VIP On and VIP Off.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Atrial Sensing to Ventricular Sensing (%PR)</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the difference in the percentage of atrial sensing to ventricular sensing (%PR) detected by the device between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Atrial Sensing to Ventricular Pacing (%PV)</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the difference in the percentage of Atrial Sensing to Ventricular Pacing (%PV) between VIP On and VIP Off. A lower percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Atrial Pacing to Ventricular Sensing (%AR)</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the difference in the percentage of Atrial Pacing to Ventricular Sensing (%AR) between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Atrial Pacing to Ventricular Pacing (%AV)</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the difference in the percentage of Atrial Pacing to Ventricular Pacing (%AV) between VIP On and VIP Off. A lower percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Experiencing a Study-Related Adverse Event</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the incidence of study-related adverse events between VIP On and VIP Off.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Auto Mode Switch Events</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>This outcome measure evaluated the difference in the number of auto mode switch events between VIP On and VIP Off.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Bradycardia</condition>
  <arm_group>
    <arm_group_label>VIP On, Then VIP Off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIP Off, Then VIP On</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intervention/treatment</intervention_name>
    <description>Device: VIP On&#xD;
Device: VIP Off</description>
    <arm_group_label>VIP Off, Then VIP On</arm_group_label>
    <arm_group_label>VIP On, Then VIP Off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has been implanted with dual chamber SJM Victory® device with VIP™ for 1 month&#xD;
             (± 2 weeks).&#xD;
&#xD;
          -  At the time of pacemaker implant, VIP™ is programmed &quot;OFF&quot;.&#xD;
&#xD;
          -  At the time of enrollment, patient is paced in the RV ≤ 60% of the time.&#xD;
&#xD;
          -  Patient is medically stable.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has evidence of complete AV block, such that ventricular pacing would be&#xD;
             required as part of the patient's routine management.&#xD;
&#xD;
          -  Patient is indicated for AF Suppression.&#xD;
&#xD;
          -  Patient has persistent or chronic atrial fibrillation.&#xD;
&#xD;
          -  Patient is unable to comply with the follow-up visits due to geographical,&#xD;
             psychological, or any other reasons.&#xD;
&#xD;
          -  Patient is currently participating in another device research study.&#xD;
&#xD;
          -  Patient is younger than 18 years of age.&#xD;
&#xD;
          -  Patient is pregnant.&#xD;
&#xD;
          -  Patients life expectancy is less than 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clay Cohorn</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2006</study_first_posted>
  <results_first_submitted>June 29, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>134 of 135 subjects were randomized. One subject was not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VIP On, Then VIP Off</title>
          <description>Participants first have the VIP algorithm programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.&#xD;
Intervention/treatment:&#xD;
Device: VIP On Device: VIP Off</description>
        </group>
        <group group_id="P2">
          <title>VIP Off, Then VIP On</title>
          <description>Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.&#xD;
Intervention/treatment:&#xD;
Device: VIP Off Device: VIP On</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 135 subjects were enrolled in the study and 134 of these 135 subjects were randomized. The 134 randomized subjects are included in the baseline analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>VIP On, Then VIP Off</title>
          <description>Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.&#xD;
Intervention/treatment:&#xD;
Device: VIP On Device: VIP Off</description>
        </group>
        <group group_id="B2">
          <title>VIP Off, Then VIP On</title>
          <description>Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.&#xD;
Intervention/treatment:&#xD;
Device: VIP On Device: VIP Off</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="16.1"/>
                    <measurement group_id="B2" value="75.6" spread="10.4"/>
                    <measurement group_id="B3" value="74.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>67/68 subjects (VIP On, then VIP Off) and 64/66 subjects (VIP Off, then VIP On) have gender information collected on the CRF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="64"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Intrinsic Ventricular Events</title>
        <description>This outcome measured evaluated the difference in the percentage of intrinsic ventricular events between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Intrinsic Ventricular Events</title>
          <description>This outcome measured evaluated the difference in the percentage of intrinsic ventricular events between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>% of intrinsic ventricular events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="28.5"/>
                    <measurement group_id="O2" value="22.8" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A target of an 80% reduction in percentage of ventricular pacing with VIP™ is proposed in this study. In order to achieve an 80% power of detecting an 80% reduction in the percentage of ventricular paced events and using a two group two-sided t-test of equal means, a minimum sample size of 39 patients per group was required. To account for possible withdrawal or loss to follow-up, this study targeted to enroll 100 patients (50 per group).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-60.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-67.5</ci_lower_limit>
            <ci_upper_limit>-52.9</ci_upper_limit>
            <estimate_desc>Mean difference in the percentage of intrinsic ventricular events is presented as, VIP Off - VIP On.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Arrhythmias</title>
        <description>This outcome measure evaluated the difference in the percentage of time a patient spent in atrial tachycardia/atrial fibrillation (arrhythmia burden) calculated by the device between VIP On and VIP Off.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Arrhythmias</title>
          <description>This outcome measure evaluated the difference in the percentage of time a patient spent in atrial tachycardia/atrial fibrillation (arrhythmia burden) calculated by the device between VIP On and VIP Off.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>percentage of burden</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="13"/>
                    <measurement group_id="O2" value="2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Atrial Sensing to Ventricular Sensing (%PR)</title>
        <description>This outcome measure evaluated the difference in the percentage of atrial sensing to ventricular sensing (%PR) detected by the device between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Atrial Sensing to Ventricular Sensing (%PR)</title>
          <description>This outcome measure evaluated the difference in the percentage of atrial sensing to ventricular sensing (%PR) detected by the device between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>percentage of PR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9" spread="34.2"/>
                    <measurement group_id="O2" value="12.3" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Atrial Sensing to Ventricular Pacing (%PV)</title>
        <description>This outcome measure evaluated the difference in the percentage of Atrial Sensing to Ventricular Pacing (%PV) between VIP On and VIP Off. A lower percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Atrial Sensing to Ventricular Pacing (%PV)</title>
          <description>This outcome measure evaluated the difference in the percentage of Atrial Sensing to Ventricular Pacing (%PV) between VIP On and VIP Off. A lower percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>percentage of PV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="18.7"/>
                    <measurement group_id="O2" value="37.4" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Atrial Pacing to Ventricular Sensing (%AR)</title>
        <description>This outcome measure evaluated the difference in the percentage of Atrial Pacing to Ventricular Sensing (%AR) between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Atrial Pacing to Ventricular Sensing (%AR)</title>
          <description>This outcome measure evaluated the difference in the percentage of Atrial Pacing to Ventricular Sensing (%AR) between VIP On and VIP Off. A higher percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>percentage of AR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="35"/>
                    <measurement group_id="O2" value="10.4" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Atrial Pacing to Ventricular Pacing (%AV)</title>
        <description>This outcome measure evaluated the difference in the percentage of Atrial Pacing to Ventricular Pacing (%AV) between VIP On and VIP Off. A lower percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Atrial Pacing to Ventricular Pacing (%AV)</title>
          <description>This outcome measure evaluated the difference in the percentage of Atrial Pacing to Ventricular Pacing (%AV) between VIP On and VIP Off. A lower percentage indicates more intrinsic ventricular events and a lower amount of unnecessary RV pacing.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>percentage of AV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="21.6"/>
                    <measurement group_id="O2" value="38.1" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Experiencing a Study-Related Adverse Event</title>
        <description>This outcome measure evaluated the incidence of study-related adverse events between VIP On and VIP Off.</description>
        <time_frame>6 months after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Period</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Experiencing a Study-Related Adverse Event</title>
          <description>This outcome measure evaluated the incidence of study-related adverse events between VIP On and VIP Off.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Auto Mode Switch Events</title>
        <description>This outcome measure evaluated the difference in the number of auto mode switch events between VIP On and VIP Off.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>VIP On</title>
            <description>VIP On Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
          <group group_id="O2">
            <title>VIP Off</title>
            <description>VIP Off Group&#xD;
VIP On, then VIP Off&#xD;
VIP Off, then VIP On</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Auto Mode Switch Events</title>
          <description>This outcome measure evaluated the difference in the number of auto mode switch events between VIP On and VIP Off.</description>
          <population>The analysis population includes patients enrolled in the study with data available on the outcome measure at 6 months after randomization.</population>
          <units>Counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="11.6"/>
                    <measurement group_id="O2" value="1.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months for each intervention</time_frame>
      <desc>Safety Population included all subjects who were randomized and received at least one of the interventions (VIP On or VIP Off).</desc>
      <group_list>
        <group group_id="E1">
          <title>VIP On</title>
          <description>VIP On Period</description>
        </group>
        <group group_id="E2">
          <title>VIP Off</title>
          <description>VIP Off Period</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>LEAD DISLODGEMENT OR MIGRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DIMINISHING R-WAVE AMPLITUDE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clay Cohorn - Director, Clinical Research</name_or_title>
      <organization>Abbott</organization>
      <phone>469-929-7116</phone>
      <email>clay.cohorn@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

